• From AKT1 Targeting to Actionable Apoptosis Data

  2026-08-19

  A translational framework for converting AKT1-directed anticancer findings into rigorous apoptosis evidence using orthogonal models, tissue-compatible workflows, and the One-step TUNEL Cy3 Apoptosis Detection Kit.

• YC-1 Workflows for Hypoxia and Cancer Research

  2026-08-18

  YC-1 combines soluble guanylyl cyclase activation with pharmacological suppression of HIF-1α signaling, making it useful for controlled hypoxia, angiogenesis, and apoptosis studies. This workflow guide translates that dual activity into reproducible cell-based assays while carefully distinguishing established cancer applications from emerging neuroprotection research.

• MLKL Polymerization, Lysosomal Leakage, and Necroptosis

  2026-08-18

  The reference study identifies lysosomal membrane permeabilization as a key execution step linking MLKL polymerization to necroptosis. Its imaging, genetic, and chemical perturbation experiments place cathepsin B release downstream of lysosomal damage and suggest a mechanistic framework for studying lysosomal protease-dependent cell death.

• Kidney-Targeted mRNA Nanoparticles: Study Insights

  2026-08-17

  This 2024 Pace University dissertation investigates how excipient selection can improve mRNA loading in polymeric mesoscale nanoparticles intended for kidney-directed delivery. Its design links loading capacity and encapsulation efficiency with particle size, cytotoxicity, pharmacokinetics, cellular uptake, and protein expression, providing a useful framework for evaluating multifunctional mRNA formulations.

• Indometacin Enhances Endogenous Remyelination

  2026-08-17

  The reference study shows that indometacin can promote oligodendrocyte differentiation, myelination, and remyelination across cellular, tissue, and animal models. Its mechanistic experiments implicate GSK3β-dependent β-catenin regulation, suggesting a repair-oriented use for an established NSAID beyond conventional anti-inflammatory activity.

• Pitavastatin (NK-104): In Vitro Protocol Guide

  2026-08-16

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibition tool for cholesterol-biosynthesis assays and related cell-based workflows. It is best used in vitro or in biochemical studies, not as a substitute for clinical treatment or unvalidated animal dosing.

• Recombinant Human Oncostatin M in Fibroblast Aging

  2026-08-15

  Discover how Recombinant Human Oncostatin M can be integrated into fibroblast-state and cytokine-response studies. This article combines product-specific assay design with mitochondrial senescence readouts from a 2025 dermal fibroblast study to support more discriminating experiments.

• Novobiocin Workflows for Antimicrobial Research

  2026-08-14

  Novobiocin combines DNA gyrase B ATPase inhibition with Hsp90-directed activity, giving researchers a flexible tool for bacterial, parasitic, and carefully controlled antiviral assays. This guide translates those mechanisms into practical workflows, assay controls, formulation choices, and troubleshooting strategies.

• Streptozotocin Workflows for Diabetes Models

  2026-08-14

  Streptozotocin, or STZ, enables controlled β-cell injury for experimental diabetes mellitus induction, therapeutic screening, and complication research. This practical guide connects model-building decisions with painful diabetic neuropathy assays, including TBK1–microglia pyroptosis readouts, while emphasizing dose selection, reagent stability, and phenotype validation.

• Proteinase K for DNA Preparation: Mechanism and Use

  2026-08-13

  Proteinase K is a broad-spectrum serine protease used for genomic DNA isolation enzyme workflows and enzyme contaminant removal for DNA prep. Its resistance to SDS and EDTA supports protein hydrolysis in molecular biology while controlled digestion helps preserve DNA integrity during protein digestion.

• SW033291: Designing Better Regeneration Assays

  2026-08-13

  SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoiesis stimulation, and tissue repair. This guide focuses on assay design, target-engagement controls, and how recent muscle-regeneration findings should shape experimental interpretation.

• IEM 1460: AMPA Receptor Blocker Workflows

  2026-08-12

  IEM 1460 enables controlled AMPA receptor inhibition assays for dissecting excitotoxicity, synaptic signaling, and neuroprotection. This workflow-focused guide connects receptor-selective experiments with lessons from a recent in vivo glutamate-receptor study while clearly separating validated findings from practical optimization recommendations.

• KG-501 for CREB–CBP Transcription Studies

  2026-08-12

  KG-501 provides a practical way to test CREB–CBP coactivator recruitment in cancer and macrophage assays, complementing receptor-level pathway experiments. This workflow connects transcriptional coactivator disruption with proliferation, differentiation, inflammatory polarization, and colorectal cancer research while preserving essential controls for compound solubility and pathway specificity.

• MitMAB: Causal Mapping of Organoid Uptake

  2026-08-11

  MitMAB enables causal analysis of dynamin-dependent uptake in intestinal organoid systems. This article connects the compound’s mechanism with organoid orientation, extracellular vesicle biology, and more defensible intracellular trafficking research decisions.

• MALAT1 Levels Shape TDP-43 RNA Binding and Cell Viability

  2026-08-11

  The reference study shows that MALAT1 abundance influences both cell survival and the distribution of TDP-43 binding across mRNA transcripts. Its results support a dosage-sensitive RNA–protein network in which MALAT1 can modify TDP-43 function, including during MPP+-induced neuronal stress.

544 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page